The role of forecasts in monetary policy

Forecasts of future economic developments play an important role for the monetary policy decisions of central banks. For example, forecasts of goal variables can help central banks achieve their goals and make them more accountable to the public. There are two primary explanations for the benefits of forecasts. The first is that monetary policy affects goal variables such as inflation and output only with substantial lags. Policy actions should, therefore, be based on forecasts of goal variables at horizons consistent with policy lags and be taken when these forecasts are inconsistent with policy goals. Under such an approach, the quality of a central bank's forecasts and the effectiveness of its actions to bring forecasts into alignment with targets provide a basis for judging the performance of policymakers and for holding them accountable.> The second, and less intuitive, explanation is that by focusing on a forecast of only one variable -- inflation -- a central bank can potentially achieve multiple goals. This approach can be successful even if there are tradeoffs among the various goal variables. For example, the approach can combine a commitment to long-run price stability with concern for the effects of monetary policy on output.> Amato and Laubach argue that the lagged effects of monetary policy make the use of forecasts necessary. They also argue that delegating a single goal—such as inflation stabilization—to the central bank facilitates accountability, but at the risk of not achieving other goals. They then examine how the Eurosystem and the Bank of England, both of which have been assigned a single goal, address the existence of tradeoffs among goals. Finally, the authors provide evidence that a monetary policy aimed primarily at stabilizing inflation forecasts—as practiced by the Bank of England, for example—can, in fact, achieve multiple goals.Forecasting ; Monetary policy ; Banks and banking, Central

The value of interest rate smoothing : how the private sector helps the Federal Reserve

Most central banks conduct monetary policy by setting targets for overnight interest rates. During the 1990s, central banks have tended to move these interest rates in small steps without reversing direction quickly, a practice called interest rate smoothing. For example, the majority of Federal Reserve policy moves in the last decade and a half have come in a sequence of 25 basis point moves, in striking contrast to the early 1980s, when short-term interest rates fluctuated widely. In light of this historical contrast, it is natural to ask whether interest rate smoothing is a desirable way to conduct monetary policy.> Amato and Laubach argue that interest rate smoothing is beneficial because the private sector is forward-looking. The private sector bases its decisions on expectations of the future. Thus, a monetary policy move today will be more effective if it is expected to persist over time. By smoothing interest rates, the size of changes in interest rates required to reduce fluctuations in the economy can be smaller than would otherwise be necessary.Monetary policy ; Interest rates ; Monetary policy - United States

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples.

MalariaGEN is a data-sharing network that enables groups around the world to work together on the genomic epidemiology of malaria. Here we describe a new release of curated genome variation data on 7,000 Plasmodium falciparum samples from MalariaGEN partner studies in 28 malaria-endemic countries. High-quality genotype calls on 3 million single nucleotide polymorphisms (SNPs) and short indels were produced using a standardised analysis pipeline. Copy number variants associated with drug resistance and structural variants that cause failure of rapid diagnostic tests were also analysed.  Almost all samples showed genetic evidence of resistance to at least one antimalarial drug, and some samples from Southeast Asia carried markers of resistance to six commonly-used drugs. Genes expressed during the mosquito stage of the parasite life-cycle are prominent among loci that show strong geographic differentiation. By continuing to enlarge this open data resource we aim to facilitate research into the evolutionary processes affecting malaria control and to accelerate development of the surveillance toolkit required for malaria elimination